Evaluation of Vitamin D levels of Patients with Type 2 Diabetes Mellitus Taking Oral Antidiabetic Drugs

Abstract

Objective: The aim of this study was to evaluate the vitamin D levels of type 2 diabetes Mellitus (T2DM) patients taking oral antidiabetic drugs. Methods: The data of 276 T2DM patients who applied to the internal medicine outpatient clinic of our hospital between January-2020 and March-2021, and the control group consisting of normoglycemic individuals in the same age group, as well as the data of 130 patients, were retrospectively reviewed from archive records. Patients with serum 25-hydroxyvitamin D (25(OH)D) level below 30 ng/mL were accepted as vitamin D deficiency and insufficiency, and patients with serum 25(OH)D levels above 30 ng/mL were accepted as normal vitamin D adequacy. The data of T2DM patients taking oral antidiabetic drugs and the data of normoglycemic control group patients were statistically compared. Results: 60.8% (n=168) of T2DM patients taking 276 oral antidiabetic drugs included in the study were female and 39.2% (n=108) were male. The mean age of the patients was 52.5±4.2 years. The mean serum 25(OH)D level of the T2DM group patients taking oral antidiabetic drugs was 9.6±4.3 ng/mL. Of the 130 patients taken as the normoglycemic control group, 65.3% (n=85) were female and 34.7% (n=45) were male. The mean age of these patients was 53.6±4.4 years. Mean serum 25(OH)D level of the control group was 16.1±4.6 ng/mL. When the 25(OH)D levels, HOMA-IR, fasting blood glucose, HbA1c and BMI ratios of the T2DM group patients taking oral antidiabetic drugs were compared statistically compared to the normoglycemic control group patients, significant differences were found between the groups (respectively; p <0.01; p < 0.01; p <0.01; p <0.01; p <0.01). Conclusion: The fact that vitamin D levels were found to be significantly lower in T2DM patients taking oral antidiabetic drugs compared to the normoglycemic control group suggests that vitamin D deficiency has an important place in the formation of T2DM. We think that early vitamin D replacement therapy in these patients may be a preventive factor in the formation of T2DM.